Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $9.20

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have received a consensus rating of “Hold” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $9.50.

Several analysts have recently weighed in on the stock. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $11.00 in a research report on Wednesday. Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 220,000 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $4.37, for a total transaction of $961,400.00. Following the transaction, the director directly owned 6,869,863 shares in the company, valued at approximately $30,021,301.31. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RXRX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock valued at $33,901,000 after purchasing an additional 4,149,346 shares in the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at about $16,040,000. Advisors Asset Management Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 753.8% in the 1st quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company’s stock valued at $706,000 after buying an additional 117,851 shares in the last quarter. Nuveen LLC bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $10,118,000. Finally, Stratos Wealth Partners LTD. grew its position in shares of Recursion Pharmaceuticals by 724.3% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 98,704 shares of the company’s stock worth $499,000 after buying an additional 86,730 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 4.1%

NASDAQ RXRX opened at $4.26 on Wednesday. The company’s 50-day moving average price is $4.95 and its 200-day moving average price is $5.13. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01. The stock has a market cap of $2.21 billion, a PE ratio of -2.37 and a beta of 0.94. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The company had revenue of $5.18 million during the quarter, compared to analyst estimates of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The firm’s revenue for the quarter was down 80.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.34) EPS. Equities research analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.